Overall, these data indicate that RXF393-bearing mice offer a unique model to test drugs against cancer cachexia and that sunitinib, as well as sorafenib, can prevent cachexia in vivo by lowering protein catabolism through inhibition of STAT3/MuRF-1 activation at least in muscles. The gene discussed is STAT3; the disease is cancer.